Tempus AI stock
TEMNASDAQTempus AI, Inc., HealthcareISIN US88023B1035
45Score 45 out of 100, Weak
Price and trend
87 / 100
Price history
+11% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 38% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 64).
The price is 6.6% below its 52-week high. Largest decline in 2 years: 60% (October 2025 to July 2026).
Chart figures for advanced users
- SMA 50$72.42
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$57.35
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)64
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$41.55
- The lowest closing price of the last twelve months.
- Resistance$85.08
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Tempus AI, Inc. belongs to the Medical (Healthcare Information Services) industry (United States) and, with a market value of $14.09B, is number 2 of 25 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.27B (up 83.4% year on year) and a loss of $245.03M.
- For fiscal 2026, analysts expect on average revenue of $1.6B (up 25.9%) and adjusted earnings per share of −$0.05.
Show more
- MEQIRI Score 45 out of 100 (Weak): rank 472 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 46.6% a year since 2020, Medical (Healthcare Information Services) median 16.5%.Growth 70
Weaknesses
- High debtDebt 2.86 times equity (latest quarter), Medical (Healthcare Information Services) median 0.34.Stability 29
- Loss-makingLoss of $189.29M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$150.63M over the last 12 months.Fundamentals 17
Its standout strengths are technical analysis and momentum, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 46 to 45.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 36.6% on the twelve months before. Revenue has grown strongly since 2019, at around 65% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 63%, operating −20%, net −19%. Last 12 months: net −13%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 23 Feb 2027in 103 days
- Last reported
- 2 Nov 2026EPS reported $0.07 (expected −$0.09)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 256.7% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.05+76.3%
- Revenue
- $1.6B+0.4%
- Earnings per share
- −$0.01−256.7%
- Revenue
- $1.99B+1.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +5.6%2026 revenue guidance raised to $1.595 billion to $1.605 billion (about 25% growth), adjusted EBITDA of about $65 million.
“We are increasing guidance to $1.595 billion-$1.605 billion in 2026, representing approximately 25% growth. We expect 2026 Adjusted EBITDA to be approximately $65 million, an improvement of about $72 million over 2025.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 9 insiders sold, $125.49M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Epstein David RSale
2 Nov 2026, Board
- Shares
- 370
- Price
- $74.29
- Value
- $27,487
- Fukushima RyanSale
2 Nov 2026, CEO, Data
- Shares
- 80
- Price
- $74.29
- Value
- $5,943
- Lefkofsky Eric PSale
27 Oct 2026, 10 percent owner, officer: CEO and Chairman
- Shares
- 250,000
- Price
- $70.36
- Value
- $17.59M
Show 41 more
- Schoenherr Thomas EdwardSale
25 Sept 2026, CEO, Diagnostics
- Shares
- 10,281
- Price
- $85.00
- Value
- $873,885
- Lefkofsky Eric PSale
22 Sept 2026, 10 percent owner, officer: CEO and Chairman
- Shares
- 250,000
- Price
- $77.47
- Value
- $19.37M
- Lefkofsky Eric PSale
17 Sept 2026, 10 percent owner, officer: CEO and Chairman
- Shares
- 200,000
- Price
- $80.57
- Value
- $16.11M
- Bartolucci Ryan MSale
17 Sept 2026, Chief Accounting Officer
- Shares
- 7,062
- Price
- $75.00
- Value
- $529,650
- Polovin AndrewSale
17 Sept 2026, EVP, Chief Legal Officer
- Shares
- 2,951
- Price
- $75.00
- Value
- $221,325
- Fukushima RyanSale
16 Sept 2026, CEO, Data
- Shares
- 700
- Price
- $70.00
- Value
- $49,000
- Fukushima RyanSale
1 Sept 2026, CEO, Data
- Shares
- 30,846
- Price
- $62.71
- Value
- $1.93M
- Doudna Jennifer ASale
1 Sept 2026, Board
- Shares
- 676
- Price
- $65.55
- Value
- $44,312
- Epstein David RSale
1 Sept 2026, Board
- Shares
- 250
- Price
- $65.55
- Value
- $16,388
- West NadjaSale
28 Aug 2026, Board
- Shares
- 3,000
- Price
- $69.00
- Value
- $207,000
- Lefkofsky Eric PSale
25 Aug 2026, 10 percent owner, officer: CEO and Chairman
- Shares
- 11,848
- Price
- $69.87
- Value
- $827,857
- Lefkofsky Eric PSale
25 Aug 2026, 10 percent owner, officer: CEO and Chairman
- Shares
- 238,152
- Price
- $68.39
- Value
- $16.29M
- Schoenherr Thomas EdwardSale
21 Aug 2026, CEO, Diagnostics
- Shares
- 2,694
- Price
- $70.00
- Value
- $188,580
- Fukushima RyanSale
21 Aug 2026, CEO, Data
- Shares
- 14,286
- Price
- $70.00
- Value
- $1M
- Schoenherr Thomas EdwardSale
19 Aug 2026, CEO, Diagnostics
- Shares
- 8,082
- Price
- $58.40
- Value
- $471,991
- Rogers James WilliamSale
19 Aug 2026, Chief Financial Officer
- Shares
- 26,313
- Price
- $60.00
- Value
- $1.58M
- Polovin AndrewSale
19 Aug 2026, EVP, Chief Legal Officer
- Shares
- 7,927
- Price
- $56.00
- Value
- $443,912
- Fukushima RyanSale
18 Aug 2026, CEO, Data
- Shares
- 41,095
- Price
- $49.61
- Value
- $2.04M
- Lefkofsky Eric PSale
18 Aug 2026, 10 percent owner, officer: CEO and Chairman
- Shares
- 132,591
- Price
- $49.61
- Value
- $6.58M
- Schoenherr Thomas EdwardSale
18 Aug 2026, CEO, Diagnostics
- Shares
- 9,232
- Price
- $49.61
- Value
- $458,000
- Rogers James WilliamSale
18 Aug 2026, Chief Financial Officer
- Shares
- 22,529
- Price
- $49.61
- Value
- $1.12M
- Polovin AndrewSale
18 Aug 2026, EVP, Chief Legal Officer
- Shares
- 22,148
- Price
- $49.61
- Value
- $1.1M
- Bartolucci Ryan MSale
18 Aug 2026, Chief Accounting Officer
- Shares
- 6,175
- Price
- $49.61
- Value
- $306,342
- West NadjaSale
14 Aug 2026, Board
- Shares
- 3,000
- Price
- $53.90
- Value
- $161,700
- Fukushima RyanSale
7 Aug 2026, CEO, Data
- Shares
- 20,000
- Price
- $50.04
- Value
- $1M
- Epstein David RSale
3 Aug 2026, Board
- Shares
- 370
- Price
- $43.40
- Value
- $16,058
- Fukushima RyanSale
3 Aug 2026, CEO, Data
- Shares
- 23,818
- Price
- $46.19
- Value
- $1.1M
- Lefkofsky Eric PSale
28 Jul 2026, 10 percent owner, officer: CEO and Chairman
- Shares
- 250,000
- Price
- $42.06
- Value
- $10.51M
- Fukushima RyanSale
8 Jul 2026, CEO, Data
- Shares
- 33,284
- Price
- $57.39
- Value
- $1.91M
- Fukushima RyanSale
6 Jul 2026, CEO, Data
- Shares
- 10,000
- Price
- $60.00
- Value
- $600,000
- Lefkofsky Eric PSale
29 Jun 2026, 10 percent owner, officer: CEO and Chairman
- Shares
- 166,250
- Price
- $57.48
- Value
- $9.56M
- Doudna Jennifer ASale
25 Jun 2026, Board
- Shares
- 2,673
- Price
- $55.00
- Value
- $147,015
- Rogers James WilliamSale
25 Jun 2026, Chief Financial Officer
- Shares
- 11,529
- Price
- $55.00
- Value
- $634,095
- Epstein David RSale
1 Jun 2026, Board
- Shares
- 250
- Price
- $49.40
- Value
- $12,350
- Lefkofsky Eric PSale
27 May 2026, 10 percent owner, officer: CEO and Chairman
- Shares
- 166,250
- Price
- $46.70
- Value
- $7.76M
- Schoenherr Thomas EdwardSale
19 May 2026, CEO, Diagnostics
- Shares
- 1,580
- Price
- $44.07
- Value
- $69,631
- Rogers James WilliamSale
19 May 2026, Chief Financial Officer
- Shares
- 10,853
- Price
- $44.07
- Value
- $478,292
- Polovin AndrewSale
19 May 2026, EVP, Chief Legal Officer
- Shares
- 8,703
- Price
- $44.07
- Value
- $383,541
- Lefkofsky Eric PSale
19 May 2026, 10 percent owner, officer: CEO and Chairman
- Shares
- 22,335
- Price
- $44.07
- Value
- $984,303
- Fukushima RyanSale
19 May 2026, CEO, Data
- Shares
- 13,550
- Price
- $44.07
- Value
- $597,149
- Bartolucci Ryan MSale
19 May 2026, Chief Accounting Officer
- Shares
- 4,116
- Price
- $44.07
- Value
- $181,392
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Tempus AI
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 45
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger and next smaller companies by market value
- BrightSpring Health ServicesBTSG $14.45B66
- Hinge HealthHNGE $9.82B70
- HealthEquityHQY $8.52B71
- M32413.T $7.7B73
- Alibaba Health Information Technology0241.HK $6.19B60
- DoximityDOCS $5.92B81
- Waystar HoldingWAY $5.55B60
- HeartflowHTFL $5.14B46
ETFs that hold Tempus AI
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Artificial Intelligence UCITS ETFXMLD | 3.08% | 0.49% | €1.96B |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 2.34% | 0.49% | €318.39M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.81% | 0.35% | €1.21B |
Show 5 more
| iShares Healthcare Innovation UCITS ETF2B78 | 0.74% | 0.40% | €1.49B |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 0.72% | 0.25% | €44.3M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.12% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.09% | 0.35% | €434.1M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.07% | 0.35% | €8.19B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 13 Jun 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.